The intuition behind screening seems airtight: catch disease early, treat it sooner, save lives. But the math of testing populations who mostly don’t have the disease is counterintuitive. When a condition is rare, even a highly accurate test produces more false positives than true ones — and each false positive triggers a chain of biopsies, scans, surgeries, and months of fear that exact a real toll.
The base-rate problem is the heart of the issue
Imagine a test that’s 95% accurate applied to a population where 1% have the disease. Out of 10,000 people, roughly 100 are sick — the test catches 95 of them. But it also flags 5% of the 9,900 healthy people, producing about 495 false positives. So a positive result means roughly an 80% chance you don’t have the disease. This isn’t a flaw in any specific test; it’s a property of screening rare conditions. Most people who hear “your test came back positive” assume it’s a near-certainty. It usually isn’t, and the gap between perceived and actual risk is where overtreatment thrives.
Follow-up procedures carry their own risks
A flagged mammogram leads to additional imaging, sometimes a biopsy. A suspicious PSA reading leads to a prostate biopsy that carries infection and bleeding risk. A coronary calcium score nudges patients toward statins, stress tests, and catheterization with its own complication rate. Every step in the cascade was triggered by an initial signal that’s often noise. Studies of breast and prostate cancer screening have estimated that for every life saved, several patients undergo treatment for cancers that would never have caused symptoms — surgeries, radiation, and hormone therapies with permanent side effects. The benefit is real but smaller than the marketing suggests, and the harms are systematically underweighted.
Anxiety and overdiagnosis are health outcomes too
The interval between an abnormal result and a definitive answer can stretch weeks. Sleep, work, relationships all suffer. Even after a benign result, follow-up scans every six months become the new normal for years. Overdiagnosis — finding disease that would never have hurt the person — is its own category of harm, because once a label exists, treatment usually follows. Thyroid cancer rates have soared in countries that adopted aggressive ultrasound screening, with no change in mortality, because the new diagnoses were tumors that wouldn’t have progressed. The patients still got surgery, lifelong hormone replacement, and a cancer entry in their charts. The treatment was real even when the threat wasn’t.
Bottom line
Screening isn’t free, and the cost isn’t just the test fee. The right question for any recommended screen is whether the population-level evidence shows that earlier detection actually changes outcomes — not whether finding things sooner sounds intuitively better. For some screens (colonoscopy in average-risk adults, cervical cancer screening), the evidence is solid. For others, it’s ambiguous or unfavorable. Asking your doctor about the number-needed-to-screen, the false positive rate, and what the next steps would look like is reasonable, not paranoid. The goal is health, not testing for its own sake.
Leave a Reply